Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 94.03B |
| Revenue (ttm) | 55.55B |
| Net Income (ttm) | 2.36B |
| Shares Out | n/a |
| EPS (ttm) | 2.04 |
| PE Ratio | 39.83 |
| Forward PE | 9.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,661,810 |
| Average Volume | 2,235,685 |
| Open | 8,236.00 |
| Previous Close | 8,235.00 |
| Day's Range | 8,211.00 - 8,480.00 |
| 52-Week Range | 4,865.00 - 8,480.00 |
| Beta | 0.70 |
| RSI | 83.22 |
| Earnings Date | Nov 5, 2025 |
About Popular
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)
Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)
Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business
See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround. Click for more on TEVA and its earnings.
Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock
A substantial insider sell was reported on November 10, by Amir Weiss , Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE: TEVA), based on the recent SEC filing. What Happened: A Form 4 fil...
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently, Teva Pharmaceutical I...
Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript
Price Over Earnings Overview: Teva Pharmaceutical Indus
In the current session, the stock is trading at $24.04, after a 0.29% spike. Over the past month, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock increased by 19.72% , and in the past year, by 40.7...
Teva (TEVA) Reveals Promising Data on AUSTEDO for Tardive Dyskinesia
Teva (TEVA) Reveals Promising Data on AUSTEDO for Tardive Dyskinesia
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the prese...
Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
JP Morgan Raises Teva Pharmaceutical (TEVA) Price Target to $28 | TEVA Stock News
JP Morgan Raises Teva Pharmaceutical (TEVA) Price Target to $28 | TEVA Stock News
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
Why Teva Pharmaceutical Stock Rocked the Market Today
The company delivered a convincing pair of beats in its third-quarter earnings report.
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth ...
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth Amidst Market Challenges
Teva Pharmaceutical (TEVA) Reports Strong Q3 2025 Growth
Teva Pharmaceutical (TEVA) Reports Strong Q3 2025 Growth
Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Teva outlines path to $2.5B AUSTEDO revenue in 2027 as innovative portfolio grows 33%
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.
Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Wednesday. Shares of Johnson Controls International PLC (NYSE: JCI) rose sharply during Wednesday's session after th...
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its third-quarter 2025 financial results on Wednesday, with total revenue of $4.48 billion, beating analysts' expectations of $4.35 billion, ...
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its third-quarter 2025 financial results on Wednesday, with total revenue of $4.48 billion, beating analysts' expectations of $4.35 billion, ac...
Teva (TEVA) Stock Surges Over 18% with Impressive Gains
Teva (TEVA) Stock Surges Over 18% with Impressive Gains
Teva Pharmaceutical Industries Limited 2025 Q3 - Results - Earnings Call Presentation
Teva Pharmaceuticals stock surges 12% as branded drug sales outperform
Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio.